GALAPAGOS NV/S (NASDAQ:GLPG) Sets New 52-Week High at $191.72

GALAPAGOS NV/S (NASDAQ:GLPG) shares hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $191.72 and last traded at $190.33, with a volume of 796 shares changing hands. The stock had previously closed at $189.63.

Several brokerages have recently issued reports on GLPG. Cowen reiterated a “buy” rating on shares of GALAPAGOS NV/S in a research note on Friday, July 26th. TheStreet upgraded GALAPAGOS NV/S from a “c” rating to a “b” rating in a research note on Tuesday, October 29th. Royal Bank of Canada lifted their price objective on GALAPAGOS NV/S to $171.00 in a research note on Monday, July 29th. Jefferies Financial Group cut GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research note on Monday, July 29th. Finally, Morgan Stanley cut their target price on GALAPAGOS NV/S to $193.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $175.22.

The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.95 and a current ratio of 8.95. The firm has a market cap of $10.35 billion, a price-to-earnings ratio of -289.92 and a beta of 1.58. The firm has a 50-day moving average price of $165.48 and a two-hundred day moving average price of $149.63.

GALAPAGOS NV/S (NASDAQ:GLPG) last issued its earnings results on Thursday, October 24th. The biotechnology company reported $8.72 earnings per share for the quarter, topping the consensus estimate of ($1.41) by $10.13. GALAPAGOS NV/S had a return on equity of 25.34% and a net margin of 32.09%. The business had revenue of $715.97 million for the quarter, compared to analyst estimates of $52.26 million. Research analysts anticipate that GALAPAGOS NV/S will post 8 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. increased its position in GALAPAGOS NV/S by 464.1% during the second quarter. JPMorgan Chase & Co. now owns 24,790 shares of the biotechnology company’s stock worth $3,162,000 after buying an additional 20,395 shares during the period. Morgan Stanley increased its position in GALAPAGOS NV/S by 1.7% during the second quarter. Morgan Stanley now owns 65,837 shares of the biotechnology company’s stock worth $8,488,000 after buying an additional 1,111 shares during the period. Ladenburg Thalmann Financial Services Inc. acquired a new position in GALAPAGOS NV/S during the second quarter worth approximately $59,000. Comerica Bank increased its position in GALAPAGOS NV/S by 4.1% during the second quarter. Comerica Bank now owns 3,036 shares of the biotechnology company’s stock worth $516,000 after buying an additional 120 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec increased its position in GALAPAGOS NV/S by 134.4% during the second quarter. Caisse DE Depot ET Placement DU Quebec now owns 29,300 shares of the biotechnology company’s stock worth $3,778,000 after buying an additional 16,800 shares during the period. 15.57% of the stock is currently owned by institutional investors and hedge funds.

About GALAPAGOS NV/S (NASDAQ:GLPG)

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

See Also: How do buyers and sellers choose a strike price?

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.